Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Lidocaine in 5% Dextrose Injection, USP

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2012

 

Summary View

WARNINGS

  • Anaphylactic reactions may occur following administration of lidocaine hydrochloride. In the case of severe reaction, discontinue the use of the drug.               

ADVERSE REACTIONS

Hematologic Effects: methemoglobinemia
  • Allergic reactions, including anaphylactic reactions, may occur but are infrequent.
-
-